Targeted protein degradation (TPD) aids in developing novel bifunctional small-molecule
degraders and eliminates proteins of interest. The TPD approach shows promising results in …

Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in
hematological malignancies that potentially circumvents many constraints of existing small …

Targeted protein degradation (TPD) through the autophagy pathway displays broad
substrate scope and is gaining increasing interest in biology and medicine. However …

Protein-degrading chimeras are superior drug modalities compared to traditional protein
inhibitors because of their effective therapeutic performance. So far, various targeted protein …

Neuroblastoma is among the most common childhood cancers. Neuroblastoma in advanced
stages is one of the most intractable pediatric cancers, notwithstanding the recent …

Niemann–Pick Type C (NPC) represents an autosomal recessive disorder with an incidence
rate of 1 in 150,000 live births, classified within lysosomal storage diseases (LSDs). The …

Chemoresistance is a significant barrier to effective cancer treatment. Potential mechanisms
for chemoresistance include reactive oxygen species (ROS) accumulation and expression of …

In mammals, right open reading frame kinase 3 (RIOK3) is related with cancer development
and immune regulation. To explore the role of teleost RIOK3 in the antiviral innate immunity …

Accumulation of misfolded proteins leads to many neurodegenerative diseases that can be
treated by lowering or removing mutant proteins. Huntington's disease (HD) is characterized …

Targeted protein degradation (TPD) technologies have become promising therapeutic
approaches through degrading disease-causing proteins via the protein degradation …